Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

Heesun J Rogers; Eric D Hsi

doi:10.1016/j.path.2013.08.007

Myeloid Neoplasms with inv(3)(q21q26.2) or t(3;3)(q21;q26.2)

Surg Pathol Clin. 2013 Dec;6(4):677-92. doi: 10.1016/j.path.2013.08.007. Epub 2013 Oct 21.

Authors

Heesun J Rogers¹, Eric D Hsi²

Affiliations

¹ Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: rogersj5@ccf.org.
² Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

PMID: 26839193
DOI: 10.1016/j.path.2013.08.007

Abstract

Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) [inv3/t(3;3)] is a distinct entity under the subgroup of AMLs with recurrent genetic abnormalities in the 2008 World Health Organization classification. Myelodysplastic syndrome (MDS) with inv3/t(3;3) has a high risk of progression to AML. AML and MDS with inv3/t(3;3) have a similarly aggressive clinical course with short overall survival (OS) and are commonly refractory to therapy. In this article, clinical and pathologic features and prognosis in AML and MDS with inv3/t(3;3) are reviewed, and other myeloid neoplasms with similar dysplastic features to be differentiated from AML and MDS with inv3/t(3;3) are discussed.

Keywords: Acute myeloid leukemia; Dysmegakaryopoiesis; Dysregulated EVI1; Multilineage dysplasia; Myelodysplastic syndrome; inv(3)(q21q26.2); t(3;3)(q21;q26.2).